Effect of Pravastatin Monotherapy in Patients with Hypercholesterolemia.
10.4070/kcj.1993.23.4.614
- Author:
Han Soo KIM
;
Sang Wook LIM
;
Young Sup YOON
;
Nam Sik CHUNG
;
Won Heum SHIM
;
Seung Yun CHO
;
Sung Soon KIM
- Publication Type:Original Article
- Keywords:
Pravastaion;
Hypercholesterolemia
- MeSH:
Blood Glucose;
Cholesterol;
Creatine Kinase;
Creatinine;
Dizziness;
Flushing;
Headache;
Humans;
Hypercholesterolemia*;
Male;
Nausea;
Oxidoreductases;
Pravastatin*;
Transaminases;
Uric Acid
- From:Korean Circulation Journal
1993;23(4):614-620
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: HMG-CoA reductase is known as a rate limiting enzyme in the synthesis of cholesterol. We studied the clinical efficacy and the side effects of pravastatin, a HMG-CoA reductase inhibitor, in patients with hypercholesterolemia. METHOD: Ten miligrams of pravastatin was administered once daily for 8 weeks in twenty five patients(7 male, 18 female) with hypercholesterolemia(>240mg/dl). Compared with pretreatment levels, pravastatin significantly decreased levels of total cholesterol(286+/-22 versus 234+/-27mg/dl, p<0.005) by 19%LDL-cholesterol(176+/-40 versus 144+/-33mg/dl, p<0.005) by 23% with significantly decreased levels of total cholesterol/HDL-cholesterol ratio(5.5+/-2.0 versus 4.8+/-1.5, p<0.05) and LDL-cholesterol/HDL-cholesterol ratio(3.4+/-1.2 versus 2.9+/-0.9, p<0.05). The level of HDL-cholesterol(52+/-17 versus 54+/-13mg/dl) and triglyceride(241+/-198 verus 178+/-111mg/dl) were not changed significantly. The side effects of pravastatin were mild and transient, including 1 case of headache, 1 dizziness, 1 facial flushing and 2 nausea. The laboratory tests including serum transaminases, uric acid, creatinine, creatine phosphokinase and blood glucose were not changed significant. CONCLUSION: Pravastatin 10mg as a single daily dose is as effective and safe as 5mg two times a day in patients with hypercholesterolemia.
